MERGERS: COMMISSION APPROVES ACQUISITION OF HOSPIRA BY PFIZER * The European Commission has approved the proposed acquisition of Hospira by Pfizer under the EU Merger Regulation. Both companies are US based and active globally in the development and marketing of human pharmaceuticals. The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development. The Commission expressed concerns that the merged entity would have faced insufficient competitive pressure from the remaining players in the corresponding markets, with a risk of price rises and discontinuation of the development of Pfizer's infliximab biosimilar drug. The commitments offered by the companies address these by removing the
The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Pfizer / Hospira)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.